Literature DB >> 12825819

Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence.

Atsuo Yoshino1, Yoichi Katayama, Takao Fukushima, Takao Watanabe, Chiaki Komine, Takakazu Yokoyama, Kaoru Kusama, Itaru Moro.   

Abstract

Clinical and histopathological evaluations are inadequate for assessing biological aggressiveness and regrowth potential in benign pituitary adenomas. To develop reliable and prognostically informative means of predicting behavior remains an intractable problem. Telomerase, a reverse transcriptase that extends telomere length, may facilitate tumorigenesis and tumor immortality. In the present study, we investigated the telomerase activity of pituitary adenomas, and attempted to assess the value of telomerase expression for predicting their clinical course. In total, 31 (30 patients) benign pituitary adenoma samples including 8 recurrent adenomas were studied. Telomerase expression was evaluated by polymerase chain reaction (PCR)-based telomeric repeat amplification protocol (TRAP) assay and telomerase activity levels were quantitated by improved PCR enzyme-linked immunosorbent assay (ELISA). The data were analyzed in relation to clinical course which was reviewed at 4-5.5 years (median follow-up time, 52.5 months) after surgery. The relative values of the telomerase expression for predicting the clinical course were compared with the MIB-1 antigen-based proliferative cell index (PCI) and p53 immunoreactivity which have recently been suggested to correlate with aggressive behavior in pituitary adenomas. Overall, telomerase expression was detected in 13% of the adenomas (4 tumor tissues, 3 patients). These adenomas comprised large, invasive, and functioning adenomas. The number of telomerase-positive adenomas was small; however, the PCI was higher in cases with telomerase expression (4 tumor tissues; mean, 4.2 +/- 2.4%) than in those without it (27 tumor tissues; 1.4 +/- 1.3%) (p = 0.01). One tumor with detectable telomerase expression, which did not undergo additional pharmacological or radiotherapeutic intervention after first surgery, recurred rapidly despite gross total surgical resection, although the PCI of both the primary and recurrent adenomas was not high. Detection of telomerase expression may represent an additional useful means of identifying aggressive behavior, complementing the histopathological evaluation of benign-appearing pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825819     DOI: 10.1023/a:1023935621976

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

2.  Telomerase activity in human gliomas.

Authors:  S Le; J J Zhu; D C Anthony; C W Greider; P M Black
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

3.  Radiotherapy in the treatment of pituitary adenomas.

Authors:  M Chun; G B Masko; S Hetelekidis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-08       Impact factor: 7.038

4.  The significant role of telomerase activity in human brain tumors.

Authors:  K Nakatani; N Yoshimi; H Mori; S Yoshimura; H Sakai; J Shinoda; N Sakai
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

5.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

6.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

7.  Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results.

Authors:  I Ciric; M Mikhael; T Stafford; L Lawson; R Garces
Journal:  J Neurosurg       Date:  1983-09       Impact factor: 5.115

8.  Telomere length predicts replicative capacity of human fibroblasts.

Authors:  R C Allsopp; H Vaziri; C Patterson; S Goldstein; E V Younglai; A B Futcher; C W Greider; C B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Correlating telomerase activity levels with human neuroblastoma outcomes.

Authors:  E Hiyama; K Hiyama; T Yokoyama; Y Matsuura; M A Piatyszek; J W Shay
Journal:  Nat Med       Date:  1995-03       Impact factor: 53.440

10.  Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas.

Authors:  M J Ebersold; L M Quast; E R Laws; B Scheithauer; R V Randall
Journal:  J Neurosurg       Date:  1986-05       Impact factor: 5.115

View more
  9 in total

Review 1.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

Review 2.  My approach to pathology of the pituitary gland.

Authors:  N Y Y Al-Brahim; S L Asa
Journal:  J Clin Pathol       Date:  2006-12       Impact factor: 3.411

3.  Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics.

Authors:  Alma Ortiz-Plata; Martha Lilia Tena Suck; Mario López-Gómez; Alfonso Heras; Aurora Sánchez García
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

4.  Telomere length and telomerase expression in pituitary tumors.

Authors:  C S Martins; B A Santana-Lemos; F P Saggioro; L Neder; H R Machado; A C Moreira; R T Calado; M de Castro
Journal:  J Endocrinol Invest       Date:  2015-05-08       Impact factor: 4.256

5.  Telomerase detection in the diagnosis and prognosis of cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

Review 6.  Prognostic indicators in pituitary tumors.

Authors:  Agustinus Suhardja; Kalman Kovacs; Oded Greenberg; Bernd W Scheithauer; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 4.056

7.  Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.

Authors:  Atsuo Yoshino; Yoichi Katayama; Akiyoshi Ogino; Takao Watanabe; Kazunari Yachi; Takashi Ohta; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2007-01-11       Impact factor: 4.506

8.  Prognostic implication of telomerase activity in patients with brain tumors.

Authors:  Choong Hyun Kim; Jin Hwan Cheong; Koang Hum Bak; Jae Min Kim; Suck Jun Oh
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

9.  Telomerase expression in clinically non-functioning pituitary adenomas.

Authors:  Liana Lumi Ogino; Elisa Baranski Lamback; Alexandro Guterres; Carlos Henrique de Azeredo Lima; Daniel Gomes Henriques; Monique Alvares Barbosa; Débora Aparecida Silva; Aline Helen da Silva Camacho; Leila Chimelli; Leandro Kasuki; Mônica R Gadelha
Journal:  Endocrine       Date:  2020-10-22       Impact factor: 3.633

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.